SCHEMBL934634

SCHEMBL934634

CCC(=O)NCc1cccc(O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.53
CYP1A2 P05177 1/20 0.53
PKM P14618 1/20 0.53
ALOX15 P16050 1/20 0.53
NFKB1 P19838 1/20 0.53
MAPK1 P28482 1/20 0.53
NLRP3 Q96P20 1/20 0.52
KMT2A Q03164 1/20 0.51
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
BLM P54132 1/20 0.51
PMP22 Q01453 1/20 0.51
ROCK2 O75116 1/20 0.50
ROCK1 Q13464 1/20 0.50
SPR P35270 1/20 0.50
SRC P12931 1/20 0.49
ALDH1A1 P00352 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13040220 0.84 MTNR1A (0.53) PKMKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL19002540 0.83 SPR (0.71) SPRMTNR1AMTNR1B
SCHEMBL8304609 0.83 MMP13 (0.57) KDM4ELMNAALDH1A1HTTSMN1; SMN2
SCHEMBL8480688 0.83 PKM (0.53) CYP3A4CYP1A2PKMALOX15NFKB1
SCHEMBL5725833 0.82 CYP1A2 (0.56) CYP3A4CYP1A2PKMALOX15NFKB1
SCHEMBL31724652 0.82 CYP1A2 (0.56) CYP3A4CYP1A2PKMALOX15NFKB1
SCHEMBL19002589 0.82 HPGD (0.56) CYP3A4CYP1A2PKMALOX15NFKB1
SCHEMBL21901089 0.82 HPGD (0.56) CYP3A4CYP1A2PKMALOX15NFKB1
SCHEMBL4926605 0.81 TPSAB1 (0.56) CYP1A2PKMKDM4EALDH1A1HTT
SCHEMBL5390715 0.81 SRC (0.61) MAPK1SRCALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3394056-B1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2021-04-14 EP disclosed
WO-2017112777-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2017-06-29 WO disclosed
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC 2017-06-22 US disclosed
WO-2011006935-A2 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE MAPK6, MAP3K6, MAPK4 CYP3A4 4589/4885CYP1A2 4411/4885PKM 1484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.